{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T05:21:49Z","timestamp":1670908909864},"reference-count":29,"publisher":"Informa UK Limited","issue":"sup3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2003,11,1]]},"DOI":"10.1080\/10428190310001623720","type":"journal-article","created":{"date-parts":[[2003,12,30]],"date-time":"2003-12-30T16:59:00Z","timestamp":1072803540000},"page":"S69-S75","source":"Crossref","is-referenced-by-count":5,"title":["Mantle Cell Lymphoma: Non-Myeloablative Versus Dose-intensive Therapy"],"prefix":"10.1080","volume":"44","author":[{"given":"Frederick B","family":"Hagemeister","sequence":"first","affiliation":[{"name":"The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030-4009, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2011,4,20]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.11.4483.bloodjournal87114483"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1269"},{"key":"CIT0003","first-page":"1922","volume":"16","author":"Hiddemann W.","year":"1998","journal-title":"results of a prospec-tive comparative analysis of the German Low-Grade Lymphoma Study Group\", Journal of Clinical Oncology"},{"key":"CIT0004","first-page":"241","author":"Williams ME.","year":"1993","journal-title":"Leukemia"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.21.9538"},{"key":"CIT0006","unstructured":"Dreyling, M.H. and Hiddemann, W. (1999) \"Prognostic factors in mantle cell lymphoma: clinical characteristics, pathology, and cell proliferation\", Proceedings of the American Society for Clinical Oncology, 18, 3a [abstract]."},{"key":"CIT0007","first-page":"1075","volume":"85","author":"Fisher RI.","year":"1995","journal-title":"A Southwest Oncology Group study\", Blood"},{"key":"CIT0008","first-page":"1664 \u20141671","volume":"15","author":"Majlis A.","year":"1997","journal-title":"correlation of clinical outcome and biologic features with three histologic variants\", Journal of Clinical Oncology"},{"key":"CIT0009","first-page":"2829","volume":"83","author":"Berger F.","year":"1994","journal-title":"a heterogeneous group of patients with distinct clinical features and outcome\", Blood"},{"key":"CIT0010","first-page":"257","volume":"6","author":"Zucca E.","year":"1995","journal-title":"\"Patterns of survival in mantle cell lymphoma\", Annals of Oncology"},{"key":"CIT0011","first-page":"13, 28 19 \u2014 282","author":"Teodorovic I.","year":"1995","journal-title":"European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. Journal of Clinical Oncology"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z"},{"key":"CIT0013","first-page":"329 \u2014 336","volume":"34","author":"Oinonen R.","year":"1996","journal-title":"clinical features, treatment and prognosis of 94 patients\", European Journal of Cancer"},{"key":"CIT0014","unstructured":"Zhou, L.J. and Tedder, T.F. (1995) CD20 workshop panel report. In Leucocyte Typing V. White Cell Differentiation Antigens \u2014 Proceedings of the Fifth International Workshop and Conference, Boston, MA, 3\u20137 November 1993, edited by S.F. Schlossman, L. Boumsell and W. Gilks et al. Pp. 511\u2014 514. Oxford: Oxford University Press."},{"key":"CIT0015","first-page":"450","volume":"15","author":"Tedder T.F.","year":"1994","journal-title":"a regulator of cell-cycle progression of B lymphocytes\", Immunology Today"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.5.1644"},{"key":"CIT0017","first-page":"18, 317 \u2014 324","author":"Foran J.M.","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"CIT0018","first-page":"1927","volume":"92","author":"Coiffier B.","year":"1998","journal-title":"a multicenter Phase II study\", Blood"},{"key":"CIT0019","first-page":"20, 1288 \u2014 1294","author":"Howard","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"CIT0020","first-page":"4212","volume":"90","author":"Andersen N.S.","year":"1997","journal-title":"\"Failure of purging in mantle cell lymphoma assessed by polymerase chain reaction of minimal residual disease\", Blood"},{"key":"CIT0021","first-page":"3803","volume":"16","author":"Khouri IF.","year":"1998","journal-title":"an active regimen for aggressive mantle cell lymphoma\", Journal of Clinical Oncology"},{"key":"CIT0022","first-page":"1293","volume":"10","author":"Khouri IF.","year":"1999","journal-title":"molecular remissions and evidence of graft-versus-malignancy\", Annals of Oncology"},{"key":"CIT0023","unstructured":"Khouri, IF., Saliba, R., Hosing, C., Korbling, M., Younes, A., Romaguera, J., et al. (2002) \"Long-term follow-up of autologous stem cell transplantation in first remission in patients with diffuse mantle cell lymphoma\", Annals of Oncology, 13, 78 [abstract 262]."},{"key":"CIT0024","unstructured":"Hiddemann, W., Dreyling, M., Pfreundschuh, M., Gisselbrecht, C., Diehl, V., Boiron, J.M., et al. (2001) \"Myeloablative radio-chemotherapy followed by autologous blood stem cell transplanta-tion leads to a significant prolongation of the event-free survival in patients with mantle cell lymphoma (MCL) \u2014 results of a prospective randomized European Intergroup Study\", Blood, 98, 861a [abstract 3572]."},{"key":"CIT0025","first-page":"77","volume":"39","author":"Romaguera J.E.","year":"2000","journal-title":"results with intensive chemother-apy without stem cell transplant in elderly patients\", Leukemia & Lymphoma"},{"key":"CIT0026","first-page":"9 \u2014 12","volume":"4","author":"Romaguera J.E","year":"2001","journal-title":"\"Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma\", Biological Therapy of Lymphoma"},{"key":"CIT0027","unstructured":"Romaguera, J., Cabanillas, F., Dang, N.H., Goy, A., Hagemeister, F.B., Fayad, L., et al. (2001) \"Mantle cell lymphoma (MCL) \u2014 high rates of complete remission (CR) and prolonged failure-free survival (FFS) with Rituxan-HyperCVAD (R-HCVAD) without stem cell transplant (SCT)\", Blood, 98, 726a [abstract 3030]."},{"key":"CIT0028","unstructured":"Gopal, AK., Petersdorf, S., Maloney, D., Eary, J., Wood, B., Rajendran, J., et al. (2001) \"High-dose 1-131-anti CD-20 antibody therapy (tositumomab), etoposide, cyclophosphamide and auto-logous stem cell transplantation for patients with relapsed or refractory mantle cell lymphoma\", Proceedings of the American Society for Clinical Oncology, 20, 280a [abstract 118]."},{"key":"CIT0029","unstructured":"Cohen, B.J., Hedrick, E., Moskowitz, C., Straus, D. and Zelentz, A. (2000) \"The cyclophosphamide\/fludarabine (CF) regimen in mantle cell lymphoma (MCL)\", Proceedings of the American Society for Clinical Oncology, 19, 15a [abstract 50]."}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428190310001623720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T16:10:31Z","timestamp":1670861431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428190310001623720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11,1]]},"references-count":29,"journal-issue":{"issue":"sup3","published-print":{"date-parts":[[2003,11,1]]}},"alternative-id":["10.1080\/10428190310001623720"],"URL":"https:\/\/doi.org\/10.1080\/10428190310001623720","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11,1]]}}}